Plain-English translation of NCT07179679 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called TQB2934, given as a subcutaneous injection (a shot under the skin), for people with multiple myeloma that has returned or become resistant to standard treatments. TQB2934 works by connecting T cells (immune cells that fight cancer) directly to myeloma cancer cells, helping your body's immune system recognize and destroy the cancer. This is an early-stage study looking at how safe the medication is and how your body processes it.
Multiple myeloma can return or stop responding to current treatments, leaving patients with limited options. This medication represents a new approach—using your own immune system in a targeted way—to help fight this difficult-to-treat cancer.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as a subcutaneous injection once a week for the first three cycles (each cycle is 28 days), then every two weeks for cycles 4–6. If your cancer responds well, the treatment schedule may shift to once every 4 weeks. You will have regular clinic visits for injections, blood tests, and scans to monitor how well the treatment is working and to check for any side effects. The study will involve approximately 6 months of active treatment, with follow-up visits afterward.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China